The content of this presentation was taken from the:
MIT Open Course Ware http://ocw.mit.edu
ES.S10 Drugs and the Brain
This was made on behalf of the final requirements for:
CEIT321 Course in Middle East Technical University
What is Psychosis? Types of Psychosis, Chemical Classification of Antipsychotic drugs, SAR of Phenothiazenes and Butyrophenones, Chemistry, IUPAC nomenclature, MOA and uses of antipsychotic drugs.
What is Psychosis? Types of Psychosis, Chemical Classification of Antipsychotic drugs, SAR of Phenothiazenes and Butyrophenones, Chemistry, IUPAC nomenclature, MOA and uses of antipsychotic drugs.
This ppt covers the classification of anti psychotics with structures and IUPAC names, MOA, uses, metabolism and side effects. Dopaminergic pathways also given
This ppt covers the classification, structures and IUPAC names, Mechanism of action and uses of individual drugs...under anticonvulsants topic..Side effects/metabolism are also given for few
Narcotic Analgesics (Opioids) What they are: Opioids are medications that mimic the activity of endorphins, substances produced by the body to control pain. They are available by prescription only. Some narcotic analgesics combine an opioid with aspirin, acetaminophen, or ibuprofen.
Narcotic and Nonnarcotic analgesic(Medicinal Chemistry)Yogesh Tiwari
Analgesics are agents that relieve pain by acting centrally to elevate pain threshold without disturbing consciousness or altering other sensory modalities.
This ppt covers the classification of anti psychotics with structures and IUPAC names, MOA, uses, metabolism and side effects. Dopaminergic pathways also given
This ppt covers the classification, structures and IUPAC names, Mechanism of action and uses of individual drugs...under anticonvulsants topic..Side effects/metabolism are also given for few
Narcotic Analgesics (Opioids) What they are: Opioids are medications that mimic the activity of endorphins, substances produced by the body to control pain. They are available by prescription only. Some narcotic analgesics combine an opioid with aspirin, acetaminophen, or ibuprofen.
Narcotic and Nonnarcotic analgesic(Medicinal Chemistry)Yogesh Tiwari
Analgesics are agents that relieve pain by acting centrally to elevate pain threshold without disturbing consciousness or altering other sensory modalities.
CdSe Quantum Dot- Fullerene Hybrid Nano-
-composite for Solar Energy Conversion: Electron
Transfer and Photoelectrochemistry. Paper presentation, DOI: 10.1021/nn204350w
These are the drugs which antagonize the receptor action of adrenaline and related drugs.
These drugs act by blocking a and/or ß-adrenergic receptors.
α-blockers
PRAZOSIN is a competitive antagonist effective in the management of hypertension. Similar drugs with longer half-lives (e.g. doxazosin, terazosin).
β-blockers
Heart - Decrease heart rate, force of contraction and cardiac output.
Blood Pressure - Decrease in blood pressure (blockage).
Respiratory System – bronchoconstriction.
Eye – Beta-blocking agents reduce intraocular pressure, especially in glaucoma. The mechanism usually reported is decreased aqueous humor production.
Metabolic - Increase LDL and decrease HDL.
Uterus - Relaxation of uterus.
Local anaesthetic - Propranolol has some local anaesthetic action
The video for this presentation is available on our Youtube channel:
https://youtube.com/allceuseducation A continuing education course for this presentation can be found at https://www.allceus.com/member/cart/index/index?c=
Unlimited Counseling CEUs for $59 https://www.allceus.com/
Specialty Certificate tracks starting at $89 https://www.allceus.com/certificate-tracks/
Live Webinars $5/hour https://www.allceus.com/live-interactive-webinars/
Patreon: https://www.patreon.com/CounselorToolbox
Pinterest: drsnipes
Youtube.com: https://www.youtube.com/user/allceuseducation
Explore the current pharmacologic interventions for alcohol and opiate dependence.
Cholinergic antagonists and blockers-Dr.Jibachha Sah,M.V.Sc,LecturerDr. Jibachha Sah
Dr. Jibachha Sah,M.V.Sc( Veterinary pharmacology, TU,Nepal),posted lecturer notes on AUTONOMIC AND SYSTEMIC PHARMACOLOGY for B.V.Sc & A.H. 6 th semester veterinary students of College of veterinary science,Nepal Polytechnique Institute, Bharatpur, Bhojard, Chitwan, Nepal.I hope this lecture notes may be beneficial for other Nepalese veterinary students. Please send your comment and suggestion .Email:jibachhashah@gmail.com,moble,00977-9845024121
Dr. Jibachha Sah,M.V.Sc( Veterinary pharmacology, TU,Nepal),posted lecturer notes on AUTONOMIC AND SYSTEMIC PHARMACOLOGY for B.V.Sc & A.H. 6 th semester veterinary students of College of veterinary science,Nepal Polytechnique Institute, Bharatpur, Bhojard, Chitwan, Nepal.I hope this lecture notes may be beneficial for other Nepalese veterinary students. Please send your comment and suggestion .Email:jibachhashah@gmail.com,moble,00977-9845024121
The content of this presentation was taken from the:
MIT Open Course Ware http://ocw.mit.edu
ES.S10 Drugs and the Brain
This was made on behalf of the final requirements for:
CEIT321 Course in Middle East Technical University
The content of this presentation was taken from the:
MIT Open Course Ware http://ocw.mit.edu
ES.S10 Drugs and the Brain
This was made on behalf of the final requirements for:
CEIT321 Course in Middle East Technical University
The content of this presentation was taken from the:
MIT Open Course Ware http://ocw.mit.edu
ES.S10 Drugs and the Brain
This was made on behalf of the final requirements for:
CEIT321 Course in Middle East Technical University
Week 10 Psychosis, antipsychotics, and parkinson's diseaseUbaldo Niña
The content of this presentation was taken from the:
MIT Open Course Ware http://ocw.mit.edu
ES.S10 Drugs and the Brain
This was made on behalf of the final requirements for:
CEIT321 Course in Middle East Technical University
The content of this presentation was taken from the:
MIT Open Course Ware http://ocw.mit.edu
ES.S10 Drugs and the Brain
This was made on behalf of the final requirements for:
CEIT321 Course in Middle East Technical University
The content of this presentation was taken from the:
MIT Open Course Ware http://ocw.mit.edu
ES.S10 Drugs and the Brain
This was made on behalf of the final requirements for:
CEIT321 Course in Middle East Technical University
Week 5 Action potentials, alcohol, and shock therapiesUbaldo Niña
The content of this presentation was taken from the:
MIT Open Course Ware http://ocw.mit.edu
ES.S10 Drugs and the Brain
This was made on behalf of the final requirements for:
CEIT321 Course in Middle East Technical University
Week 4 Drug addiction, dopamine, and liking vs. wantingUbaldo Niña
The content of this presentation was taken from the:
MIT Open Course Ware http://ocw.mit.edu
ES.S10 Drugs and the Brain
This was made on behalf of the final requirements for:
CEIT321 Course in Middle East Technical University
The content of this presentation was taken from the:
MIT Open Course Ware http://ocw.mit.edu
ES.S10 Drugs and the Brain
This was made on behalf of the final requirements for:
CEIT321 Course in Middle East Technical University
The content of this presentation was taken from the:
MIT Open Course Ware http://ocw.mit.edu
ES.S10 Drugs and the Brain
This was made on behalf of the final requirements for:
CEIT321 Course in Middle East Technical University
The content of this presentation was taken from the:
MIT Open Course Ware http://ocw.mit.edu
ES.S10 Drugs and the Brain
This was made on behalf of the final requirements for:
CEIT321 Course in Middle East Technical University
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
2. WHAT IS AN ALCOHOL
ANTAGONIST?
An alcohol antagonist is a drug that specifically blocks the
effects of alcohol. If you take an alcohol antagonist and then
drink a bunch of alcohol, it should theoretically prevent you
from getting drunk, or it should at least reduce your level of
drunkenness.
3. REMINDER!!!
What is a receptor antagonist?
• A receptor antagonist is a drug that binds to a receptor but does
not send any signal. A receptor antagonist can block other
ligands from binding. In this way, an antagonist can block the
effects of agonists, whether those agonists are drugs or
neurotransmitters.
4. REMINDER!!!
Receptors:
• Excitatory: Sends signals (action potentials)
• Inhibitory: Blocks signals
Drugs, neurotransmitters, and other ligands:
• Agonists: Stimulate receptors, mimic the neurotransmitter
• Antagonists: Block receptors
5. Some alcohol antagonists are
receptor antagonists, but many are
not. Do not be confused.
Alcohol has many different
mechanisms of action, so there are
many different classes of alcohol
antagonists.
6. GABAA ANTAGONISTS
The GABAA receptor complex has separate binding sites for
several different classes of drugs. The GABAA receptor complex
is shaped like a donut with a number of dimples (depressions)
where drugs can bind. The center donut hole is a chloride ion
channel.
7. The GABAA receptor complex binds the neurotransmitter GABA in one
location, it binds barbiturates in a second location, it binds
benzodiazepines in a third location, it binds neurosteroids in a fourth
location, and it binds picrotoxin in a fifth location. Alcohol binds in a
sixth location that is adjacent to the benzodiazepine binding site.
GABAA ANTAGONISTS
8. GABAA: GABA BINDING SITE
ANTAGONISTS
Bicuculline – This is an alkaloid found in several different
plants. It causes stimulation, anxiety, and seizures. Bicuculline
is used to simulate epilepsy in animals.
9. GABAA: BARBITURATE SITE
ANTAGONISTS
Bemegride (a.k.a. megimide) – This drug is occasionally used to
reverse barbiturate overdose. It causes stimulation, anxiety,
and seizures. Barbiturate overdose causes death by respiratory
failure, because the patient just stops breathing. Barbiturate
overdose is a popular means of suicide and lethal injection,
because it is very peaceful.
10. Although bemegride is the specific antidote to barbiturate overdose, it is
not commonly used anymore because of side effects. Today, barbiturate
overdose is treated by mechanically ventilating the patient until the
barbiturates have worn off. Bemegride can also be used to stimulate
breathing in the absence of barbiturate overdose. For instance,
bemegride can increase respiratory rate in opioid overdose patients.
GABAA: BARBITURATE SITE
ANTAGONISTS
11. Flumazenil – This drug is occasionally used to reverse
benzodiazepine overdose, reverse benzodiazepine sedation
after surgery, and relieve drowsiness in patients with a disease
called primary hypersomnia. Flumazenil causes stimulation,
anxiety, and seizures.
GABAA: BENZODIAZEPINE SITE
ANTAGONISTS
12. Benzodiazepine overdose almost never causes death, unless
the patient has also taken other drugs such as opioids or
alcohol. Because benzodiazepine overdose is generally non-
fatal, flumazenil is usually not necessary.
GABAA: BENZODIAZEPINE SITE
ANTAGONISTS
13. GABAA: ETHANOL SITE
ANTAGONISTS
Ro 15-4513 – This drug is a benzodiazepine receptor partial
inverse agonist. It causes stimulation, anxiety, and seizures. Ro
15-4513 binds in the benzodiazepine binding cleft, but it has
an azido group sticking out that occupies the ethanol binding
cleft.
14. Most benzodiazepine ligands do not interfere with ethanol binding, but
Ro 15-4513 does interfere with ethanol binding because of this bulky
azido group that displaces ethanol. In vitro, Ro 15-4513 competitively
inhibits ethanol binding to the GABAA receptor complex. In vivo, Ro 15-
4513 inhibits the sedation caused by alcohol but does not interfere with
the anxiety relief caused by alcohol.
GABAA: ETHANOL SITE
ANTAGONISTS
15. Among the 4 drugs discussed so far, Ro 15-4513 is unique. Bicuculline,
bemegride, and flumazenil all work by causing stimulation which
counteracts the sedation caused by ethanol. Ro 15-4513 actually
prevents ethanol from binding to its molecular target. However, ethanol
has many molecular targets, and Ro 15-4513 only blocks one of them.
GABAA: ETHANOL SITE
ANTAGONISTS
16. Ro 15-4513 is a much more effective alcohol antagonist than flumazenil,
which is interesting because Ro 15-4513 is a less potent stimulant. This is
because Ro 15-4513 only binds to a few types of benzodiazepine
receptor, whereas flumazenil binds to (and blocks) almost all types.
GABAA: ETHANOL SITE
ANTAGONISTS
17. Ro 15-4513 was originally investigated as a possible treatment
for alcohol overdose. It was abandoned because it tends to
cause seizures, and also because it has a very short half-life.
GABAA: ETHANOL SITE
ANTAGONISTS
18. GABAB ANTAGONISTS
Saclofen – This drug is used only in experiments. Saclofen is
structurally related to baclofen, which is the classic GABAB
agonist.
19. OPIOID RECEPTOR ANTAGONISTS
Ethanol causes the release of endogenous opioids (e.g. beta-
endorphin). Remember that opioids are very important in the
liking pathway, meaning that opioids cause pleasure.
20. OPIOID RECEPTOR ANTAGONISTS
Naltrexone – The FDA has approved naltrexone (as pills) for alcohol
dependence. If a recovering alcoholic takes naltrexone and then slips up
and drinks a glass or two of liquor, the naltrexone will block the positive
feelings usually induced by alcohol. The alcoholic may then reconsider
their actions, and they may decide to stop drinking. Without naltrexone,
the first two drinks usually lead to ten more drinks and a full relapse.
21. Naltrexone blocks ethanol-induced pleasure, but it does not
block ethanol-induced sedation, ataxia, or nausea. Naltrexone
still qualifies as an alcohol antagonist because it blocks one
specific effect of alcohol. Naltrexone could be called a selective
alcohol antagonist.
OPIOID RECEPTOR ANTAGONISTS
22. DOPAMINE RECEPTOR
ANTAGONISTS
Ethanol causes the release of dopamine in the nucleus
accumbens. Remember that dopamine in this location
is absolutely critical to the wanting pathway, which
leads to addiction.
23. Haldol (haloperidol) – This is a potent D2 receptor antagonist,
it is widely prescribed as an antipsychotic. Normal rats will self-
administer ethanol, but rats treated with Haldol will not. This
seems to indicate that taking Haldol along with alcohol will
block the learning processes that lead to addiction, at least in
rats and at certain doses.
DOPAMINE RECEPTOR
ANTAGONISTS
24. Injecting a dopamine receptor antagonist directly into
the nucleus accumbens will inhibit self-administration
while minimizing other side effects.
DOPAMINE RECEPTOR
ANTAGONISTS
25. Like naltrexone, Haldol is a selective alcohol antagonist. Haldol
does not block most of the effects of ethanol, and it will
actually increase the level of drowsiness. However, Haldol
selectively blocks the effect of ethanol on the wanting
pathway.
DOPAMINE RECEPTOR
ANTAGONISTS
26. Dopamine antagonists can prevent a rat from learning to self-
administer alcohol, but what if the rat has already learned to
self-administer? In this case, the dopamine antagonist is much
less effective. This means dopamine antagonists are only
mildly effective for human alcoholics. Dopamine antagonists
also cause serious side effects, such as tardive dyskinesia.
DOPAMINE RECEPTOR
ANTAGONISTS
27. 5-HT3 SEROTONIN RECEPTOR
ANTAGONISTS
5-HT3 serotonin receptors are involved with nausea and
vomiting. Serotonin induces feelings of fullness and nausea,
especially when serotonin binds to and activates 5-HT3
receptors.
28. Ethanol also binds to and activates 5-HT3 receptors. Specifically, ethanol
has been shown to bind to 5-HT3A receptors, and ethanol stabilizes the
open configuration of the 5-HT3 ion channel. The 5-HT3 ion channel
conducts sodium ions, so it is excitatory. Ethanol and serotonin both
cause nausea and vomiting by stimulating the 5-HT3 receptor. (Ethanol
also causes nausea by creating acetaldehyde in the stomach lining, and
other effects.)
5-HT3 SEROTONIN RECEPTOR
ANTAGONISTS
29. Zofran (ondansetron) – Ondansetron is a highly selective 5-HT3
antagonist. Ondansetron is widely used to prevent
chemotherapy-induced nausea and vomiting.
5-HT3 SEROTONIN RECEPTOR
ANTAGONISTS
30. Ondansetron is also used to prevent nausea and vomiting
caused by other things such as radiation therapy, surgery, and
viral gastroenteritis (norovirus and rotavirus, “the stomach
bug”).
5-HT3 SEROTONIN RECEPTOR
ANTAGONISTS
31. As you would expect, ondansetron functions as a selective alcohol
antagonist that selectively blocks the nausea. However, ondansetron
doesn’t just block alcohol-induced nausea. Low doses of ethanol cause
locomotor stimulation in rats (they run around more), and this response
shows sensitization. This means that after repeated ethanol doses, the
rats actually run around even more
5-HT3 SEROTONIN RECEPTOR
ANTAGONISTS
32. Sensitization is the opposite of tolerance. Ondansetron blocks
ethanol-induced locomotor sensitization. This may indicate
that ondansetron can block alcohol addiction, much like
Haldol (a dopamine antagonist).
5-HT3 SEROTONIN RECEPTOR
ANTAGONISTS
33. Limited human trials have also shown that ondansetron is
helpful for recovering alcoholics. Ondansetron reduces the
urge to drink alcohol and also reduces the anxiety that
alcoholics feel when they don’t drink.
5-HT3 SEROTONIN RECEPTOR
ANTAGONISTS